by SD-AbarceoPharma | May 23, 2025 | Diabetes, News & Press releases, VDAC1
We are proud to present groundbreaking data at the 5th Swedish Diabetes Summit, revealing a novel approach to treating type 2 diabetes through VDAC1 oligomerization inhibitors. We share our exciting poster presented by our Principal Scientist Ruchi Jain and our...
by SD-AbarceoPharma | Oct 4, 2018 | Diabetes, VDAC1
Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi, world-class experts in beta cell biology, discovered that hyperglycemia increases VDAC1 expression and is mistargeted to the beta cell surface in Type 2 diabetes patients. Read...
Recent Comments